Analyst Price Target is $25.00
▼ -4.62% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Embecta in the last 3 months. The average price target is $25.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -4.62% upside from the last price of $26.21.
Current Consensus is
The current consensus among 1 contributing investment analysts is to sell stock in Embecta.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.